This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Who May Qualify: - Age ≥ 18 years - Relapsed or refractory to at least 2 prior systemic treatment regimens - At least 1 bi-dimensionally measurable lesion (≥ 1.5 cm) in longest dimension - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 - Adequate bone marrow, cardiac, pulmonary, renal, and hepatic function Who Should NOT Join This Trial: - CLL, or Richters transformation - Prior solid organ transplant - Prior allogeneic stem cell transplant - ASCT within 100 days prior to the first LTZ-301 administration - Prior CAR-T within 60 days prior to the first LTZ-301 administration - Current central nervous system (CNS) lymphoma - Known history of human weakened immune system virus (HIV) seropositivity - Active autoimmune conditions (where your immune system attacks your own body) - History of clinically significant cardiovascular disease - symptomatic deep vein thrombosis (DVT) within 3 months of enrollment - History of other malignancy within 3 years prior to screening Always talk to your doctor about whether this trial is right for you.